We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Requests Stronger Warning for GSK's Paxil
FDA Requests Stronger Warning for GSK's Paxil
December 9, 2005
The FDA called on GlaxoSmithKline (GSK) Dec. 8 to strengthen the warning on its top-selling antidepressant Paxil to alert consumers that clinical studies in pregnant women demonstrate the drug poses a risk to the fetus.